

Reference Data

2nd Quarter - Fiscal Year 2020
(April 1, 2020 to September 30, 2020)

Consolidated Earnings

- Consolidated Financial Data p. 1
- Consolidated Balance Sheets p. 2
- Consolidated P/L Statement p. 3
- Consolidated Sales Breakdown by Segment/Category p. 4
- Consolidated Operating Profit by Segment p. 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations
 - Sales by Region p. 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations p. 6
- Capital Expenditure p. 7
- Depreciation and Amortization p. 7
- R&D Expenses p. 7
- Result of Major Consolidated Subsidiary
 - ♦ Taisho Pharmaceutical p. 8
- Major Subsidiaries and Affiliates p. 9
- Shareholders Information p.10
- Prescription Pharmaceutical Operations:
 - New Drug Development-Taisho Pharmaceutical p.11
- Launch of New Products p.12

Consolidated Financial Data

(Millions of yen)

	March 2020(FY2019)***				March 2021(FY2020)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Net sales	60,260	132,208	211,338	288,527	75,023	145,900	289,500
(YOY%)	(-2.4%)	(+2.1%)	(+5.7%)	(+10.3%)	(+24.5%)	(+10.4%)	(+0.3%)
Self-Medication operations	42,936	97,492	157,824	220,027	56,436	113,657	235,900
Prescription Pharmaceutical operations	17,323	34,716	53,513	68,500	18,587	32,243	53,600
Gross profit on sales*	41,305	87,937	134,302	180,333	47,228	93,575	180,900
Selling, general and administrative expenses	32,981	73,412	117,215	159,196	37,838	77,279	160,900
Research and development expenses	4,991	10,669	16,179	22,876	4,209	9,429	21,200
(% Sales)	(8.3%)	(8.1%)	(7.7%)	(7.9%)	(5.6%)	(6.5%)	(7.3%)
Advertising expenses	4,800	11,753	19,557	26,046	6,107	11,905	25,600
Sales promotion expenses	5,474	13,126	20,571	27,440	5,827	12,404	25,400
Personnel expenses	6,838	14,767	23,327	31,017	8,201	16,522	32,900
Operating Profit	8,324	14,525	17,086	21,137	9,389	16,295	20,000
(YOY%)	(+2.0%)	(-14.5%)	(-39.2%)	(-32.3%)	(+12.8%)	(+12.2%)	(-5.4%)
Earnings before the amortization of goodwill and trademarks	9,263	16,904	22,039	29,470	12,399	22,233	32,600
Ordinary Profit	7,649	14,609	20,273	24,474	11,117	18,859	23,000
(YOY%)	(-37.3%)	(-35.7%)	(-43.9%)	(-40.1%)	(+45.3%)	(+29.1%)	(-6.0%)
Profit attributable to owners of parent	11,006	14,784	17,793	20,172	6,064	11,294	13,000
(YOY%)	(-19.6%)	(-65.2%)	(-65.4%)	(-58.5%)	(-44.9%)	(-23.6%)	(-35.6%)
Comprehensive income	5,301	7,916	8,800	8,470	3,537	10,802	-
(YOY%)	(-57.9%)	(-81.2%)	(-80.2%)	(-82.4%)	(-33.3%)	(+36.4%)	-
Basic EPS (yen)	137.91	185.23	222.93	252.74	75.98	141.51	162.89
Diluted EPS (yen)	137.77	185.02	222.67	252.44	75.89	141.34	162.69
BPS (yen)	8,917.17	8,956.34	8,897.27	8,887.84	8,862.95	8,949.88	8,963.26
Dividend per share (yen)	-	50.00	-	110.00	-	50.00	100.00
Payout ratio	-	-	-	43.5%	-	-	61.4%
Capital expenditure	987	2,910	5,048	9,469	2,659	5,701	20,800
Depreciation and amortization	2,391	5,228	8,894	12,610	3,673	7,206	15,700
Total assets	840,345	875,018	865,374	864,974	858,187	861,043	871,000
Shareholders' equity	741,565	743,866	740,040	739,778	736,944	744,157	746,000
Return on equity (%)**	-	-	-	2.8%	-	-	1.8%
Return on assets (%)**	-	-	-	2.4%	-	-	1.5%
Equity ratio (%)	84.7%	81.7%	82.1%	82.0%	82.4%	83.0%	82.1%
Overseas sales	7,874	21,146	42,312	69,500	27,063	47,518	93,900
Overseas sales ratio (% of total sales)	13.1%	16.0%	20.0%	24.1%	36.1%	32.6%	32.4%
Number of employees	8,105	9,493	9,428	9,354	9,356	9,304	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

*** Figures for FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

<Reference>

• E=Estimates

• Full year forecasts for the fiscal year ending March 31, 2021 were announced on May 14, 2020.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2019		End of FY2020/2Q		change	
	(March 31, 20)	% total	(Sep. 30, 20)	% total		
(Assets)						
I Current assets:	355,623	41.1%	355,246	41.3%	-376	
Cash and deposits	223,814		237,150		+13,335	
Notes and accounts receivable-trade	65,463		58,141		-7,322	
Marketable securities	14,089		5,015		-9,073	
Inventories	43,371		48,938		+5,567	
Other	8,884		6,000		-2,884	
II Fixed assets:	509,351	58.9%	505,797	58.7%	-3,554	
(1) Tangible fixed assets:	112,648	(13.0%)	111,486	(12.9%)	-1,162	
Buildings and structures	53,999		52,607		-1,392	
Machinery, equipment and vehicles	15,059		14,503		-556	
Land	38,170		38,887		+717	
Other	5,418		5,487		+68	
(2) Intangible fixed assets:	221,811	(25.6%)	215,546	(25.0%)	-6,264	
Goodwill	133,169		128,687		-4,481	
Sales rights	690		621		-68	
Trademarks	73,144		70,083		-3,061	
Software	6,570		7,854		+1,284	
Other	8,236		8,299		+62	
(3) Investments and other assets:	174,891	(20.2%)	178,764	(20.8%)	+3,872	
Investment securities	145,831		150,641		+4,809	
Shares of subsidiaries and affiliates	11,644		11,819		+174	
Net defined benefit assets	4,642		4,871		+228	
Deferred tax assets	11,134		9,854		-1,280	
Other	1,638		1,577		-60	
Total assets	864,974	100.0%	861,043	100.0%	-3,930	
(Liabilities)						
I Current liabilities:	66,456	7.7%	58,058	6.7%	-8,397	
Notes and accounts payable-trade	18,045		16,047		-1,997	
Accounts payable	15,743		14,437		-1,305	
Accrued income taxes	5,414		4,059		-1,354	
Provision for bonuses	3,769		4,582		+813	
Other	23,482		18,930		-4,552	
II Long-term liabilities:	58,739	6.8%	58,827	6.8%	+87	
Net defined benefit liabilities	21,029		21,290		+261	
Deferred taxes liabilities	30,042		30,394		+351	
Other	7,666		7,141		-525	
Total liabilities	125,196	14.5%	116,886	13.6%	-8,309	
(Net assets)						
I Shareholders' equity	692,768	80.1%	699,310	81.2%	+6,541	
Common stock	30,000		30,000		-	
Capital surplus	-		13		+13	
Retained earnings	698,223		704,727		+6,503	Profit attributable to owners of parent+11,294, Payment of dividend
Treasury stock	-35,454		-35,430		+24	
II Accumulated other comprehensive income	16,605	1.9%	15,047	1.7%	-1,557	
Valuation difference on securities	20,796		23,175		+2,379	
Foreign currency translation adjustment	-1,145		-5,203		-4,057	
Remeasurements of defined benefit plans	-3,046		-2,924		+121	
III Share acquisition rights	773	0.1%	805	0.1%	+32	
IV Non-controlling interests	29,630	3.4%	28,993	3.4%	-637	
Total net assets	739,778	85.5%	744,157	86.4%	+4,379	
Total liabilities and net assets	864,974	100.0%	861,043	100.0%	-3,930	

* Figures for the previous fiscal year have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

Consolidated P/L Statement

(Millions of yen)

	FY2019		FY2020		YOY change	
	2Q	% total	2Q	% total		
Net sales	132,208	100.0%	145,900	100.0%	+13,691	
Cost of sales	44,383	33.6%	52,369	35.9%	+7,986	
Gross profit on sales	87,825	66.4%	93,531	64.1%	+5,705	
Provision for sales returns	-112		-43		+68	
Gross profit	87,937	66.5%	93,575	64.1%	+5,637	
Selling, general and administrative expenses	73,412	55.5%	77,279	53.0%	+3,866	
Research and development expenses	10,669		9,429		-1,239	
Advertising expenses	11,753		11,905		+152	
Sales promotion expenses	13,126		12,404		-721	
Personnel expenses	14,767		16,522		+1,755	
Other	23,096		27,016		+3,920	
Operating Profit	14,525	11.0%	16,295	11.2%	+1,770	
Non-operating income	3,636	2.8%	2,772	1.9%	-864	
Non-operating expenses	3,552	2.7%	208	0.1%	-3,344	FY2019: Foreign exchange losses 3,432
Ordinary Profit	14,609	11.1%	18,859	12.9%	+4,250	
Extraordinary income	6,098	4.6%	3	0.0%	-6,094	FY2019: Gains attributable to phased acquisition 6,093
Extraordinary losses	118	0.1%	470	0.3%	+352	
Profit before income taxes and minority interests	20,589	15.6%	18,393	12.6%	-2,196	
Income taxes	5,626	4.3%	5,983	4.1%	+356	
Profit	14,962	11.3%	12,409	8.5%	-2,553	
Profit attributable to non-controlling interests	178	0.1%	1,115	0.8%	+936	
Profit attributable to owners of parent	14,784	11.2%	11,294	7.7%	-3,489	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Self-Medication operations	42,936	97,492	157,824	220,027	56,436	113,657	235,900
(YOY%)	(+1.0%)	(+8.6%)	(+14.5%)	(+22.2%)	(+31.4%)	(+16.6%)	(+7.2%)
Japan	34,428	74,576	112,985	147,062	28,772	64,584	138,700
Overseas	7,821	21,093	42,254	69,440	26,953	47,409	93,900
Other	687	1,822	2,584	3,523	710	1,663	3,300
Prescription Pharmaceutical operations	17,323	34,716	53,513	68,500	18,587	32,243	53,600
(YOY%)	(-10.0%)	(-12.6%)	(-13.8%)	(-15.9%)	(+7.3%)	(-7.1%)	(-21.8%)
Ethical drugs	16,682	33,699	52,160	67,022	18,194	31,691	53,000
Other	640	1,017	1,352	1,477	392	551	600
Total	60,260	132,208	211,338	288,527	75,023	145,900	289,500

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2020(FY2019)**				March 2021(FY2020)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Self-Medication operations	7,032	12,905	13,633	18,694	5,483	12,526	21,800
(YOY%)	(-7.2%)	(-23.4%)	(-48.0%)	(-38.3%)	(-22.0%)	(-2.9%)	(+14.6%)
Earnings before the amortization of goodwill and trademarks	7,971	15,284	18,587	27,027	8,494	18,464	34,400
Prescription Pharmaceutical operations (YOY%)	1,605	2,381	4,743	4,144	4,466	4,857	300
	(+77.2%)	(+93.9%)	(+43.2%)	(+54.4%)	(+178.1%)	(+104.0%)	(-92.8%)
Other*	-313	-761	-1,290	-1,702	-561	-1,087	-2,100
(YOY%)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Total	8,324	14,525	17,086	21,137	9,389	16,295	20,000

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

** Figures for FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E	YOY
Japan	34.4	74.6	113.0	147.1	28.8	64.6	-13.4%	138.7	-5.7%
Lipovitan series	12.8	28.3	40.7	50.9	10.4	24.4	-13.9%	46.6	-8.4%
Pabron series	5.8	12.7	22.1	29.8	3.5	9.1	-28.4%	26.6	-10.9%
RiUP series	3.6	8.1	11.8	14.9	3.5	7.6	-6.4%	14.3	-3.7%
Biofermin series	2.5	5.6	8.3	10.7	2.4	4.9	-13.3%	9.9	-8.0%
VICKS series	0.7	1.6	3.2	4.3	0.5	1.4	-14.8%	3.7	-13.8%
GI treatment series	0.9	1.8	2.9	3.7	0.8	1.6	-13.4%	3.5	-4.8%
Livita series	0.8	1.7	2.5	3.4	0.8	1.5	-8.5%	3.2	-5.0%
NARON series	0.7	1.6	2.4	3.1	0.8	1.6	-5.1%	3.0	-3.5%
Colac series	0.8	1.6	2.5	3.2	0.8	1.5	-5.2%	3.0	-6.8%
Overseas	7.8	21.1	42.3	69.4	27.0	47.4	+124.8%	93.9	+35.2%
Asia	7.2	19.3	30.1	42.5	11.5	19.6	+1.5%	44.6	+5.0%
Europe and America	0.5	1.1	11.3	25.8	15.0	27.2	-	48.3	+87.5%
Others	0.7	1.8	2.6	3.5	0.7	1.7	-8.7%	3.3	-6.4%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E	YOY
Lipovitan series	12.8	28.3	40.7	50.9	10.4	24.4	-13.9%	46.6	-8.4%
Lipovitan D	8.3	18.2	26.1	32.1	6.9	15.9	-12.9%	28.8	-10.3%
Others	4.5	10.1	14.7	18.7	3.5	8.5	-15.7%	17.8	-5.2%
(100mL other Lipovitans)	3.0	6.7	9.9	12.5	2.2	5.5	-18.1%	11.5	-7.5%
(50mL other Lipovitans)	1.5	3.4	4.8	6.3	1.3	3.0	-11.0%	6.2	-0.7%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Brands of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E	YOY
Edirol	6.5	13.8	20.9	27.0	7.3	11.6	-16.0%	14.4	-46.7%
Lusefi	1.9	3.2	5.1	7.1	2.6	5.2	+62.0%	9.8	+37.4%
Bonviva	1.6	3.3	5.1	6.6	1.7	3.4	+3.1%	6.9	+4.8%
LOQOA	0.9	1.9	3.0	3.9	0.9	1.9	-0.3%	4.0	+2.7%
Biofermin	1.0	2.2	3.0	3.8	1.1	1.8	-16.6%	4.0	+5.2%
Geninax	0.8	1.8	3.4	3.9	1.8	2.2	+23.7%	3.1	-21.0%
Clarith	1.1	2.1	3.4	4.3	0.5	1.0	-50.6%	2.8	-34.4%
Palux	0.8	1.7	2.5	3.1	0.6	1.2	-26.6%	2.3	-26.8%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Total capital expenditure	987	2,910	5,048	9,469	2,659	5,701	20,800
Taisho Pharmaceutical	748	2,414	3,556	6,471	1,081	3,258	10,750
Production department	67	494	672	1,597	358	652	1,450
Research department	38	195	370	940	37	764	1,030
Head Office and the others	642	1,724	2,512	3,933	684	1,841	8,270
Other subsidiaries	238	495	1,492	2,998	1,578	2,443	10,050

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Depreciation and amortization	2,391	5,228	8,894	12,610	3,673	7,206	15,700
Cost of sales	749	1,601	2,991	4,325	1,393	2,687	6,200
SGA expenses	1,641	3,627	5,902	8,284	2,280	4,519	9,500

* Figures for FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

Consolidated: R&D Expenses

(Millions of yen)

	March 2020(FY2019)				March 2021(FY2020)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Total R&D expenses	4,991	10,669	16,179	22,876	4,209	9,429	21,200
Self-Medication operations	1,398	2,908	4,589	6,754	1,578	3,469	7,400
Prescription Pharmaceutical operations	3,592	7,760	11,590	16,121	2,630	5,960	13,800

Result of Major Consolidated Subsidiary

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2020(FY2019)				March 2021(FY2020)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E	YOY
Net Sales	51.8	110.0	167.6	217.5	48.9	98.7	-10.3%	192.2	-11.6%
Self-Medication	34.6	75.4	114.2	149.2	30.3	66.5	-11.8%	138.7	-7.0%
Prescription Pharmaceutical	17.2	34.6	53.4	68.3	18.6	32.2	-6.9%	53.6	-21.6%
Operating profit	6.6	11.2	16.8	19.9	5.7	10.3	-7.8%	19.7	-0.8%
Ordinary profit	3.9	11.3	18.2	20.9	11.7	17.6	+55.2%	23.3	+11.6%
Profit	2.9	10.0	13.1	14.9	9.4	13.8	+38.3%	17.1	+14.9%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of September 30, 2020)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspha Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Major Shareholders (As of end of September 2020)

Major Shareholders

(Thousands of Shares)

Shareholder	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.78%
Shoji Uehara	7,754	9.71%
Uehara Museum	3,900	4.88%
Sumitomo Mitsui Banking Corp.	3,000	3.76%
MUFG Bank, Ltd.	3,000	3.76%
The Master Trust Bank of Japan, Ltd. (Trust account)	2,929	3.67%
Akira Uehara	2,143	2.68%
Custody Bank of Japan, Ltd. (Trust account)	1,717	2.15%
Kajima Corporation	1,650	2.07%
Custody Bank of Japan, Ltd. (Sumitomo Mitsui Trust Bank, Limited Reinvest Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.92%

*Shares less than one thousand are rounded down.

*Treasury stock of 5,253 thousand shares are excluded from the above as these shares do not have voting rights.

*The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	21.74%
Financial Instruments Firms	0.45%
Other companies	39.14%
Foreign Companies	13.16%
Individuals and Others	25.51%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 5,253 thousand shares.

(Rounded to the nearest second decimal place)

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of October 29, 2020

In Japan

Phase 3

TS-152 (Injection)

< Application	> Rheumatoid arthritis
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)- α antibody
< Remarks	> Generic name: Ozoralizumab

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Overseas

Phase 2

TS-121 (Oral)

< Target disease	> Depression
< In-house/Licensed-in	> In-house

Phase 1

TS-134 (Oral)

< Target disease	> Schizophrenia
< In-house/Licensed-in	> In-house

TS-161 (Oral)

< Target disease	> Depression
< In-house/Licensed-in	> In-house

TS-142 (Oral)

< Target disease	> Insomnia
< In-house/Licensed-in	> In-house

Launch of New Products

As of October 29, 2020

New Products Since FY2020 1Q Earnings Announcement (August 5, 2020)

Self-Medication Operations

Lipovitan D Space Brothers Bottle

< Description > Five types of bottles are available featuring the wise sayings of characters from the popular manga Space Brothers. The outer case (for 10 bottles) features a new image of Space Brothers with Lipovitan D drawn by its author Chuya Koyama.

< Launch > August 2020

Taisho Gastrointestinal Agent G

< Description > Active ingredient sofalcone controls the secretion of gastric acid to protect the stomach, while also alleviating heartburn and stomachache induced by acid reflux. The Taisho Gastrointestinal Agent series allows consumers to choose the most suitable gastrointestinal agent according to their condition.

< Launch > September 2020

Taisho Gastrointestinal Agent Balancer

< Description > Three types of digestive enzymes and crude drugs that keep the stomach healthy assist with digestion, movement of the stomach, and improve indigestion and discomfort induced by fat accumulated in the stomach. Suitable for children aged three and older. The Taisho Gastrointestinal Agent series allows consumers to choose the most suitable gastrointestinal agent according to their condition.

< Launch > September 2020

Taisho Gastrointestinal Agent P

< Description > Tiquizium bromide inhibits the secretion of gastric acid and controls excess movement of the stomach and intestines. It exerts an effect on acute, sharp pain in the stomach and abdomen. The Taisho Gastrointestinal Agent series allows consumers to choose the most suitable gastrointestinal agent according to their condition.

< Launch > September 2020

Pabron Nourishment Drink Alpha

< Description > Caffeine-free oral liquid formulation containing taurine, five types of crude drugs and three types of vitamins is a nutritional supplement when suffering from a cold, and helps the body to maintain and improve its strength. It is available in an easy-to-drink honey ginger flavor.

< Launch > September 2020

Launch of New Products

As of October 29, 2020

New Products Since FY2020 1Q Earnings Announcement (August 5, 2020)

Self-Medication Operations

VICKS Medicated Drops Sugarless Acerola Flavor

- < Description > Designated quasi-drug lozenge that helps improve unpleasant symptoms, including a hoarse voice, throat irritation and a sore throat induced by inflammation of the throat. It is available in the popular acerola flavor.
- < Launch > September 2020

Colac Fiber plus

- < Description > Laxative that contains two types of non-irritating ingredients: dietary fiber (Plantago ovata testa powder) and magnesium hydroxide. Dissolve in water or hot water to allow it to soften and swell. It helps improve constipation by encouraging bowel movements.
- < Launch > October 2020

Lipovitan DX

- < Description > Take once (three tablets) a day to consume 500 mg of taurine that boosts energy and vitamins B1, B2, and B6. Ideal for those who feel fatigue in the daily life or those who still feel exhausted the following day.
- < Launch > October 2020

Pabron Sore Throat Medicine

- < Description > Two types of anti-inflammatory agents act on the causes of inflammation. It treats a sore, swollen throat induced by tonsillitis and pharyngitis. It can be taken without water, on an empty stomach, as soon as symptoms develop because it does not contain ingredients that cause drowsiness. Suitable for children aged seven and older. The grapefruit-flavored chewable tablets that dissolve quickly in the mouth are easy to swallow, even for children.
- < Launch > October 2020

RiUP Regenne

- < Description > Hair essence for women contains minoxidil, an ingredient that helps promote hair growth. The bottle was updated to make measuring and application easier. The package now features a new, gorgeous yet approachable design with vivacious women in mind.
- < Launch > October 2020
-

Launch of New Products

As of October 29, 2020

New Products Since FY2020 1Q Earnings Announcement (August 5, 2020)

Self-Medication Operations

Regenne SHAMPOO / Regenne TREATMENT

< Description > RiUP Regenne shampoo and conditioner, which helps moisturize hair, promote resilience and beautiful volume, are indispensable for daily care for women's hair. The unique, salon-quality formula was developed especially for mature hair and scalps. Two types of finish are available for both shampoo and conditioner: "smooth & voluminous" or "moist & voluminous."

< Launch > October 2020

ALFE deep essence

< Description > Energy drink that contains iron, which plays an important role in enhancing beauty, ceramide, hyaluronic acid, collagen, as well as chamomile and perilla to improve health and beauty. It is easy to drink, and is available in a rich green grape and lychee flavor. (Does not contain fruit juice.) Caffeine-free. Fat-free, only 9 kcal per bottle.

< Launch > October 2020

Lipovitan D: The Second Limited Bottle Featuring Asteroid Explorer Hayabusa 2

< Description > Five types of exclusively designed labels are available, each featuring a carefully selected scene from the movie "HAYABUSA 2 REBORN." The outer case (10 bottles) also features Hayabusa 2 completing its mission and returning to Earth.

< Launch > October 2020

TOKUHON AROMA series

< Description > A plaster agent that suppresses the odor peculiar to plaster agents and uses a unique technology to combine a faint scent prepared by a fragrance expert. Three types are available: "TOKUHON AROMA R" with a sweet rose scent, "TOKUHON AROMA S" with a refreshing soap floral scent, and "TOKUHON Clear" with a faint scent.

< Launch > October 2020

Lipovitan D Featuring the Japan National Rugby Team

< Description > Two types of limited bottles are available in red and blue, each featuring the cherry blossom emblem of the Japan national rugby union team on its label. The exclusive outer case (10 bottles) also features players from the national team.

< Launch > October 2020

Launch of New Products

As of October 29, 2020

New Products Since FY2020 1Q Earnings Announcement (August 5, 2020)

Self-Medication Operations

AdryS Active Eye Cream

< Description > Medical eye cream that contains three types of medical active ingredients: heparinoid, placenta extract and vitamin E. They provide the dry eye area with moisture and refine the skin's texture to create a beautiful eye area with a brighter impression, imbued with radiance and resilience.

< Launch > October 2020
